As the literature involving EACA use in craniosynostosis is limited, further studies investigating its optimal dosing, interactions with erythropoietin, as well as other effects are necessary to elucidate the true applications of this therapeutic agent. The gene discussed is EPO; the disease is craniosynostosis.